Clinical Trial

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Study acronym: ATTAIN-PAD
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
Protocol Amendment History 2 changes
notable Trial sites expanded: 150 -> 154 locations 2026-07-19
notable Trial sites expanded: 140 -> 150 locations 2026-07-08
Trial Details
NCT Number NCT07223593
Lead Sponsor Eli Lilly and Company
Conditions Peripheral Arterial Disease
Enrollment 1,205 participants
Start Date 2025-10-31
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-17